ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Aug 13, 2015
Big Pharma Earnings Continued…
Amgen, AstraZeneca, Merck, and Pfizer...
Jul 28, 2015
Quick Take: Gilead Blows By 2Q Estimates; Investors Getting Drug Pipeline for Free
We continue to like the company that found a way to cure hepatitis C.
Jul 17, 2015
J&J’s Quarterly Results Not Reflective of Underlying Strength
On the surface, Johnson & Johnson’s second-quarter results weren’t that great, but let’s take a closer look at the performance.
Jun 16, 2015
Target-CVS Agreement: What It Really Means
Target and CVS recently signed a major partnership, but a Best Ideas Newsletter portfolio holding may benefit the most from the agreement. Let’s take a closer look at effects of the deal.
May 20, 2015
The Tax Man Cometh Anyway?
Yahoo! may not be able to ditch the IRS. What does it mean for Alibaba?
Feb 4, 2015
The Savvy Strategy of Gilead's Management
Gilead investors’ only thing to fear is fear itself?
Jan 9, 2015
January 5-9: The Week That Was - Drowning in Crude
Let’s cover new developments during the first week of 2015.
Jan 5, 2015
4 Opportunistic Stocks To Consider Buying in 2015
The Valuentum Buying Index has registered a high rating in the past on these four investment ideas. 2015 may mark strong gains for these gems.
Dec 26, 2014
HCV Competition Not New “News” for Gilead
Gilead is trading more than 40% above its 52-week low and about 20% from its 52-week high. We see no reason to panic, and the company’s trading activity more closely reflects a company whose stock price has quintupled in recent years than one that is in any trouble whatsoever. Gilead’s shares bounced right off technical support levels, and we see a long term that is still very bright for the biotech. Gilead’s shares remain underpriced even under a bear-case scenario.
Dec 3, 2014
Gilead Sciences: The Going Rate for a Stock Analyst These Days?
A nickel an hour…think about it. Now a 6.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.